Abstract: A method for simulating a deep-brain stimulation in a computer-assisted platform that includes providing to a neurosurgeon, through a man-machine interface, visual information of a pre-operative situation, including a representation of a brain. The method also includes monitoring inputs of said neurosurgeon on the man-machine interface, until a trajectory is determined between an entry point and a target for the placement of an electrode. The method further includes comparing said trajectory to a set of previously-established trajectories for the pre-operative situation, so as to determine an overall measurement representative of a quality of the trajectory compared to the previously-established trajectories.

Abstract: The disclosure relates to the use of clofoctol in the prevention or treatment of a disease caused by a coronavirus, in particular Covid-19.

Abstract: An ultrasound cardiac stimulation system includes: a system for measuring the heart electrical activity; a system for generating a beam of focussed ultrasound signals focussed on a targeted zone, the signals being calibrated to generate electrical stimulation in a zone of the heart, the beam generation being synchronised with a first selected time of the electrocardiogram, the generation of the beam corresponding to a pulse with a duration of less than 80 ms; a system for locating the targeted zone coupled with a system for positioning the system for generating the focussed beam to control the beam of focussed ultrasound signals in the targeted zone, the location system being synchronised with the system for generating the beam of focussed signals; a single monitoring system following in real time a temperature and tissue deformation in the targeted zone, the monitoring system taking measurements in synchronisation with the rhythm of the electrocardiogram.

Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

Abstract: A method for determining a region in which the actual concentration is located, in a medium, of a substrate made up of any molecule likely to undergo catalysed oxidation-reduction by a catalyst. The method includes the following steps: taking at least one group of at least two biosensors, each biosensor having a calibration curve of the signal induced by the oxidation-reduction reaction and having identical initial portions of their calibration curves up to a concentration value of the substrate from which the measurement of the signal differ; and when more than one group is present, the biosensors in different groups having different calibration curves without identical initial portions; placing the biosensors in contact with the medium; measuring the signal induced by the oxidation or reduction reaction for each biosensor in the group/groups; comparing all the signal values produced by the biosensors and following the method described in the description.

Abstract: The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).

Abstract: A method for in vitro prognosis of the outcome of an individual afflicted by an acute myeloid leukaemia. The method includes the following steps: (a) measuring the expression level of genes involved in 5 DNA repair pathways, (b) calculating a score value for each DNA repair pathway group of genes, and (c) classifying the individual as having a good or a bad outcome.

Abstract: A device intended to be implanted in a human or animal body, in order to produce hydrogen in situ from molecules present in the body medium in which the device is implanted, this device having an anode and a cathode, which are each electrically connected to a pole of an electrical energy source, and having a semi-permeable material separating the electrodes from the body medium, in which device, when the connection to the electrical energy source is effective in situ, in the presence of body fluid, a closed electrical circuit is formed, with production of hydrogen at the cathode, the semi-permeable material having a cutoff threshold of between 50 and 500 Da.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: The invention relates to chimeric antigen receptors (CARs) targeting a cancer-associated antigen and their use for treatment of a tumor or cancer. In particular, the invention provides compositions and methods for treating diseases associated with the antigen NGcGM3. The invention also relates to CARs specific to NGcGM3, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to NGcGM3.

Abstract: Some embodiments are directed to a method for preparing a skin substitute, a dermal substitute, to a skin substitute, to a dermal substitute and to a kit for implementing the method. Some other embodiments are directed to a graft that can consist of of a skin substitute and to the use thereof as treating a skin disorder and/or a loss of skin substance.

Abstract: The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the ?I7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the ?62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.

Abstract: Vaccines for preventing or treating diabetes, obesity and complications thereof are provided. The vaccines comprise at least one active agent such as attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a cDNA from Porphyromonas gingivalis.

Abstract: Disclosed is a non-invasive method for assessing in a subject the presence and severity of a liver lesion, or the risk of death or liver-related events, including: 1) performing at least three binary logistic regressions on at least one variable, performed on the same variable(s) but each directed to a different single diagnostic target, thereby obtaining at least three scores; 2) combining the scores from step 1) in a multiple linear regression to obtain a new multi-targeted score; 3) optionally sorting the multi-targeted score obtained in step 2) in a classification of liver lesion stages or grades, thereby determining to which liver lesion stage or grade the subject belongs based on his/her multi-targeted score. Also disclosed is a single multi-targeted non-invasive test obtained by the combination of single-targeted non-invasive tests providing a unique score and a unique classification with improved accuracy compared to single-targeted diagnostic tests.

Abstract: A system for ablating or monitoring a zone of the heart, includes a system to measure the heart electrical activity; a phased array for generating a beam of focussed ultrasound signals on a targeted zone of the heart; an imaging system determining an image of a transcostal wall projected in an image plane of the phased array by taking into consideration a position and direction of the phased array and making it possible to deactivate elements of the phased array in accordance with the position of the elements with regard to the position of the projected image of the transcostal wall; a positioning system to control the position of a focussed zone of a beam of focussed ultrasound signals on the targeted zone, a monitoring system to measure a temperature and tissue deformation in the targeted zone; and a device for measuring a level of cavitation in the targeted zone.

Abstract: A method for identifying a microorganism to be identified, which includes the following steps: obtaining an Excitation-Emission EEM of the microorganism to be identified, analysing the main components of the EEM matrix using at least one reference EEMr matrix, projecting the result of the analysis onto a plane defined by two main components, and identifying the microorganism to be identified.

Abstract: The invention concerns a biocompatible oily ferrofluid comprising iron-oxide based magnetic nanoparticles and an oil phase comprising at least one fatty acid ester, characterized in that said magnetic nanoparticles are surface functionalized by molecules of one or more phospholipids, and in particular a biocompatible oily ferrofluid comprising iron-oxide based magnetic nanoparticles and an oil phase comprising at least one fatty acid ester, said iron-oxide based magnetic nanoparticles forming a colloidal dispersion in said oil phase from a temperature belonging to the range from 20 to 80° C.

Abstract: A method of segmentation of a three-dimensional image for generating a model of a myocardial wall includes recording a three-dimensional image of a wall of the myocardium, the wall delimiting at least one cavity of the heart; segmenting a continuous part of the wall into at least a first volume having a thickness less than a first predefined thickness threshold of between 0 and 5 mm and a second volume of a continuous part of the wall having a thickness greater than the first threshold; generating a model of the wall of the myocardium, where the continuous part of the wall of the myocardium is modelled according to at least two volumes that continue each other.

Abstract: The invention relates to the use of an iron-score based on the expression level of at least 1 gene, in particular at least 3, preferably at least 5, and even preferably 8 genes selected in the group consisting of APEX1, TFRC, HIF1A, ABCG2, SCARA3, IREB2, SFXN4 and SLC39A14 involved in the iron metabolism, as a prognosis marker in subjects having MCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.

Abstract: A new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.